Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19

Tamara Tanner; Dawn M. Wahezi

doi:10.1016/j.prrv.2020.07.003

Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19

Tamara Tanner, Dawn M. Wahezi

Pediatrics

Research output: Contribution to journal › Review article › peer-review

22 Scopus citations

Abstract

The rapid spread of SARS-CoV-2 infection globally coupled with the relatively high case-fatality rate has led to immediate need for therapeutic intervention to prevent and treat COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 may be exacerbated by a dysregulated host immune response resulting in significant hyperinflammation and cytokine release. The aim of this review is to describe the basis for the immune dysregulation caused by SARS-CoV-2 infection and to examine current investigations into immunomodulatory therapies aimed at targeting the excessive host immune response.

Original language	English (US)
Pages (from-to)	81-87
Number of pages	7
Journal	Paediatric Respiratory Reviews
Volume	35
DOIs	https://doi.org/10.1016/j.prrv.2020.07.003
State	Published - Sep 2020

Keywords

Children
Immune dysregulation
Multi-system inflammatory syndrome [MIS-C]
SARS-CoV-2
Treatment

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.prrv.2020.07.003

Cite this

@article{b1871288270440758d5f027d0c67f29c,

title = "Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19",

abstract = "The rapid spread of SARS-CoV-2 infection globally coupled with the relatively high case-fatality rate has led to immediate need for therapeutic intervention to prevent and treat COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 may be exacerbated by a dysregulated host immune response resulting in significant hyperinflammation and cytokine release. The aim of this review is to describe the basis for the immune dysregulation caused by SARS-CoV-2 infection and to examine current investigations into immunomodulatory therapies aimed at targeting the excessive host immune response.",

keywords = "Children, Immune dysregulation, Multi-system inflammatory syndrome [MIS-C], SARS-CoV-2, Treatment",

author = "Tamara Tanner and Wahezi, {Dawn M.}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Ltd",

year = "2020",

month = sep,

doi = "10.1016/j.prrv.2020.07.003",

language = "English (US)",

volume = "35",

pages = "81--87",

journal = "Paediatric Respiratory Reviews",

issn = "1526-0542",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19

AU - Tanner, Tamara

AU - Wahezi, Dawn M.

PY - 2020/9

Y1 - 2020/9

N2 - The rapid spread of SARS-CoV-2 infection globally coupled with the relatively high case-fatality rate has led to immediate need for therapeutic intervention to prevent and treat COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 may be exacerbated by a dysregulated host immune response resulting in significant hyperinflammation and cytokine release. The aim of this review is to describe the basis for the immune dysregulation caused by SARS-CoV-2 infection and to examine current investigations into immunomodulatory therapies aimed at targeting the excessive host immune response.

AB - The rapid spread of SARS-CoV-2 infection globally coupled with the relatively high case-fatality rate has led to immediate need for therapeutic intervention to prevent and treat COVID-19 disease. There is accumulating evidence that morbidity and mortality in COVID-19 may be exacerbated by a dysregulated host immune response resulting in significant hyperinflammation and cytokine release. The aim of this review is to describe the basis for the immune dysregulation caused by SARS-CoV-2 infection and to examine current investigations into immunomodulatory therapies aimed at targeting the excessive host immune response.

KW - Children

KW - Immune dysregulation

KW - Multi-system inflammatory syndrome [MIS-C]

KW - SARS-CoV-2

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=85089259433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089259433&partnerID=8YFLogxK

U2 - 10.1016/j.prrv.2020.07.003

DO - 10.1016/j.prrv.2020.07.003

M3 - Review article

C2 - 32792288

AN - SCOPUS:85089259433

SN - 1526-0542

VL - 35

SP - 81

EP - 87

JO - Paediatric Respiratory Reviews

JF - Paediatric Respiratory Reviews

ER -

Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this